- Innovation Insights
- Business Professionals
- IP Strategists
- IP Practitioners
- Products & Services
- About PatentSight
With the novel coronavirus spreading both fear and illness across the world, it is a worthwhile exercise to look at the patent landscape of antiviral vaccines. By analyzing both the quality and quantity of the patent portfolios of the world's leading manufacturers and researchers, it is possible to evaluate the companies and research institutes that are at the forefront of finding vaccines and cures for potentially deadly viral diseases.
Join our webinar to learn more about:
Gene Quinn is the President and founder of IPWatchdog.com, a patent attorney, law professor, and leading commentator on patent law and innovation policy. Gene’s writing typically focuses on pending legislation, rule making at the United States Patent and Trademark Office, and general commentary about the state of the industry. Gene practices patent law with Widerman Malek, and the majority of his patent practice is focused on software patents and Internet innovations. Since 2000 he has also been a principal lecturer in the PLI Patent Bar Review Course.
An expert from a leading pharmaceutical company will join the panel
More information to be added soon.
William Mansfield is the Head of Consulting and Customer Success at LexisNexis® PatentSight®. He is responsible for overseeing the negotiation, creation, and delivery of PatentSight’s global consulting projects, along with managing the Customer Success team. He works closely with numerous international and Fortune 500 companies to ensure effective deployment of patent analyses for Business Strategy, M&A Due Diligence, Portfolio Management, and other cases. With an Economics background and experience in Market and R&D strategy in the semiconductor industry, Will approaches patent analytics with an eye on business value creation.
02. April | Thursday | 18:00 CET | 12:00 pm (noon) ET